SPARBACT

Indications

• Bacterial infections
• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• Bone and joint infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations in paediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the type and severity of infection.

Mechanism of action

The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Pharmacodynamics

Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent that demonstrates in vitro activity against a wide range of microorganisms. It works by inhibiting DNA gyrase, an essential enzyme that controls DNA topology and facilitates critical processes such as replication, repair, and transcription. Although cross-resistance has been noted between sparfloxacin and other fluoroquinolones, some bacteria resistant to other fluoroquinolones may still respond to treatment with sparfloxacin.

Pharmacokinetics

The pharmacokinetics of sparfloxacin include absorption, distribution, metabolism, and excretion characteristics typical of fluoroquinolones. It is well absorbed following oral administration and exhibits a volume of distribution that allows for effective tissue penetration. The drug is metabolized in the liver and primarily excreted via renal pathways, with both unchanged drug and metabolites present in urine.

Contra-indications

• Hypersensitivity to sparfloxacin or any component of the formulation
• History of tendon disorders related to fluoroquinolone use
• Pregnancy

Adverse effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Insomnia
• Rash
• Tendon rupture
• Photosensitivity

Interactions

• Antacids containing magnesium or aluminum may reduce the absorption of sparfloxacin
• Concurrent use with other fluoroquinolones may lead to increased risk of adverse effects
• Increased effects of anticoagulants such as warfarin may occur

Precautions

• Use with caution in patients with a history of seizures or central nervous system disorders
• Monitor for signs of tendon damage, particularly in older patients
• Consider potential for QT interval prolongation in patients with relevant risk factors

Pregnancy

Sparfloxacin should not be used during pregnancy due to potential risks to the fetus.

Breast-feeding

Sparfloxacin is excreted in breast milk; caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Injectable solution

Mechanism of action

The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Pharmacodynamics

Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.